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improve outcomes. [12] [13] [14] Furthermore, the European guidelines on management of major bleeding and coagulopathy following trauma recommend a restricted volume replacement strategy to achieve target blood pressure until bleeding can be controlled and administration of vasopressors in addition to fluids to maintain target arterial pressure in the presence of life-threatening hypotension. 15 The latter recommendation, however, was graded 1C, which is a strong recommendation with low-quality or very low-quality evidence. 15 Thus, new drugs that stabilize haemodynamics, reduce resuscitation fluid requirements and lack adverse effects that are associated with vasopressor treatment could have the potential to significantly improve outcomes in patients with traumatichaemorrhagic shock. Recently, we provided initial evidence that inhibitors of Kv7 voltage-activated potassium channels could fill this gap. 16, 17 Kv7 voltage-activated potassium channels are important regulators of the membrane potential in excitable cells, such as cardiac and vascular myocytes. [18] [19] [20] [21] Kv7 channels function to stabilize resting membrane potential and suppress cell excitability. 19 Recent studies suggested that pharmacological treatments that suppress the activity of vascular Kv7 channels can promote vasoconstriction and increase peripheral vascular resistance. 18 We showed that intravenous administration of Kv7 channel inhibitors administered as single bolus injections or as supplements to crystalloid resuscitation fluids dose-dependently reduce fluid requirements to maintain haemodynamics in short-term models of fixed blood pressure haemorrhagic shock in rats. 16, 17 Because further characterization of the therapeutic potential and possible side effect profile of Kv7 channel inhibition after haemorrhagic shock is required to enable transition of this new therapeutic approach into clinical practice, the aim of the present study was to perform a detailed efficacy testing of Kv7 channel inhibition in various preclinical models of haemorrhagic shock. Thus, in the present study, we tested the effects of the selective Kv7 channel inhibitor linopirdine utilizing well-characterized lethal and non-lethal haemorrhagic shock models in spontaneously breathing and mechanically ventilated rats over clinically relevant time periods. We selected linopirdine for these studies as it has previously undergone safety pharmacology testing in humans and has also been evaluated as a cognition-enhancing drug in clinical trials. [22] [23] [24] Although linopirdine failed to improve cognitive function in Alzheimer's disease, no adverse side effects, except elevated alanine transferase levels, were noted during oral administration for up to 6 months. In the second set of experiments, linopirdine (3 mg/kg) or vehicle were administered 15 minutes after the start of the haemorrhage period F I G U R E 1 Linopirdine pre-treatment in lethal haemorrhagic shock without fluid resuscitation. Arrows: Time points of drug administration. Open squares, vehicle (n = 3); grey squares, 1 mg/kg linopirdine (n = 5); black squares, 3 mg/kg linopirdine (n = 3). Data are mean ± SE. A, Mean arterial blood pressure (MAP), mm Hg. B, Percent total blood volume (%TBV) haemorrhage. C, Kaplan-Meier survival curves (Figure 2 ). Baseline MAPs were comparable among groups. Although MAP was slightly higher in animals after linopirdine treatment, these differences did not reach statistical significance. Median survival times were 173 minutes for vehicle-treated animals and 188 minutes for animals treated with 3 mg/kg linopirdine (Figure 2c , P > .05).
| Series 2: Linopirdine treatment of spontaneously breathing rats during resuscitation from haemorrhagic shock
Next, we tested the effects of a single i.v. dose of 3 mg/kg linopirdine at the beginning of fluid resuscitation from 30 minutes of haemorrhagic shock in spontaneously breathing animals. Physiological parameters were comparable between the vehicle and linopirdine treatment groups at baseline (Figure 3 ). There were no differences in haemorrhage volumes to achieve the MAP target of 25 mm Hg during the shock period ( Figure 3A ,B). All animals could be resuscitated with normal saline to a resuscitation MAP target of 70 mm Hg ( Figure 3B ) and haematocrit values were comparable between the groups ( Figure 3C ). In all animals lactate plasma concentrations increased to 9-10 mmol/L at the end of the shock period and nor- P > .05) wet-dry weight ratios, resuscitation with NS supplemented with 25/50 μg/mL linopirdine significantly reduced colon wet-dry weight ratios ( Figure 5D , post-test for linear trend: P < .05). Table 1 shows the analyses of various routine laboratory parameters and inflammation markers in plasma at the end of the experiments (t = 300 minutes). Except for total plasma protein concentrations, which were significantly higher in animals resuscitated with 25/50 μg/mL linopirdine, there were no statistically significant differences between any of the other parameters among the groups.
Similarly, measurements of inflammation markers and superoxide dismutase activities, a key anti-oxidative enzyme, in tissue extracts did not reveal significant differences among groups ( 
| D ISCUSS I ON
In the present study, we further characterized the effects of Kv7 channel blockade with linopirdine in various rat models of haemorrhagic shock. There are several new findings from the present study. To address the therapeutic potential of linopirdine-supplemented resuscitation fluids in clinically more relevant scenarios, we then resuscitated mechanically ventilated animals for 4.5 hours. In these experiments, a higher dose of isoflurane was required to prevent spontaneous breathing, which has been reported to impair cardiac contractility, systemic vascular resistance and blood pressure in rats. [27] [28] [29] [30] Consistent with these haemodynamic consequences of isoflurane, we observed in pilot experiments that mechanically ventilated animals could not survive the haemorrhage and resuscitation protocols that we used in spontaneously breathing animals.
Accordingly, we adjusted the MAP targets for mechanically ventilated animals during the shock and resuscitation periods to 40
and 60 mm Hg, respectively. Despite the reduced severity of haemorrhagic shock and the lower MAP target during resuscitation in mechanically ventilated rats, fluid requirements to achieve the resuscitation target with NS alone were more than three-fold higher Linopirdine has previously been described to antagonize kynurenine induced hypotension, a natural tryptophan metabolite implicated in the pathophysiology of sepsis, 39 and to protect against myocardial ischaemia-reperfusion injury. 40 Thus, it might be speculated that the efficacy profile of linopirdine extends beyond haemorrhagic hypovolemic shock. Considering that linopirdine has a short systemic half-life after intravenous injection and its fluid-sparing effects wear off within three plasma half-lives, linopirdine appears to be a drug that is easily controllable if adverse effects would occur. Our findings justify further efficacy testing of linopirdine in other preclinical fluid resuscitation Analytes were measured in tissue extracts from animals after resuscitation with normal saline (NS) alone (n = 5) and animals resuscitated with NS supplemented with 10 μg/mL (n = 3) or 25/50 μg/mL (n = 5) linopirdine. TNF, tumor necrosis factor; IL, interleukin; SOD, superoxide dismutase. There were no statistically significant differences among groups. TNFα (pg/mL) 11 ± 2 3 ± 1 8 ± 3
TA B L E 1 Plasma routine laboratory parameters and cytokine concentrations
IL-6 (pg/mL) 16 ± 11 56 ± 41 20 ± 6
IL-10 (pg/mL) 24 ± 5 57 ± 37 47 ± 22
Analytes were measured in plasma obtained at t = 300 minutes from animals after resuscitation with normal saline (NS) alone (n = 5) and animals resuscitated with NS supplemented with 10 μg/mL (n = 3) or 25/50 μg/ mL (n = 5) linopirdine. GGT, gamma-glutamyl transferase. ALT, alanine aminotransferase; TNF, tumor necrosis factor; IL, interleukin. * P < .05 vs NS alone. models, such as large animal models or other models of haemorrhagic shock, septic shock or ischaemia-reperfusion injury. If successful, such data on the repurposing of linopirdine as a resuscitation fluid supplement could quickly lead to the transition towards clinical trials. 
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| Series 2: Linopirdine treatment of spontaneously breathing rats during resuscitation from haemorrhagic shock
We utilized a model of fixed blood pressure haemorrhage, as described in detail previously. 17, 41 Animals were anaesthetized and instrumented as in Series 1. Animals were haemorrhaged to a mean arterial blood pressure (MAP) of 25 mm Hg for 30 minutes. At the end of the 30-minute shock period, 0.5 mL NS (n = 6) or 3 mg/kg linopirdine (n = 6) in 0.5 mL NS were injected as an intravenous bolus injection. This treatment was followed by resuscitation with NS to a MAP of 70 mm Hg until t = 240 minutes. At the end of resuscitation period, rats were killed (isoflurane inhalation, bilateral pneumothorax). Gross necropsy was performed, and tissue from lung, small intestine (jejunum), colon and skeletal (pectoral) muscle were collected, snap frozen in liquid nitrogen and stored at −80°C until further processing.
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| Arterial blood gases and routine laboratory parameters
Arterial blood gases and routine laboratory parameters were analyzed using the Element point of care veterinary blood gas, electrolyte and critical care analyzer and the DryChem 7000 veterinary chemistry analyzer (Cuattro Veterinary USA, Loveland, CO, USA).
| Wet weight to dry weight ratios
The ratio of the tissue wet weight to dry weight was determined gravimetrically, as previously described.
43,44
| Tissue extract preparation
Snap frozen tissues were homogenized 1:5 weight/volume in a 1/10 phosphate buffered saline, 1% sodium orthovanadate, 0.5% phenylmethylsulfonyl fluoride and centrifuged at 16 100 × g at 4°C for 30 minutes. The supernatants were aliquoted and stored at −80°C until further processing.
| Superoxide dismutase (SOD) activity
The SOD activity, an important antioxidant defense system in cells, was measured in tissue extracts utilizing the SOD Assay kit-WST (Sigma Aldrich) according to the manufacturer's recommendation and expressed as SOD/mg protein.
| Enzyme linked immunosorbent assays (ELISA)
Concentrations of cytokines (tumor necrosis factor (TNF)α, interleukin (IL)6 and IL10) were measured in plasma and tissue extracts utilizing the DuoSet ELISA Development kits (R&D Systems, Minneapolis, MN, USA) according to the manufacturer's recommendations. Tissue extract cytokine concentrations are expressed as pg/mg protein.
| Protein quantification
Protein concentrations were measured with the Bio-Rad RC DC Protein Assay kit as per manufacturer's recommendations.
| Data analyses and statistics
Data are described as mean ± standard error (SE). Data were analyzed with one-way analysis of variance (ANOVA) and Dunnett's multiple comparisons test or with two-way ANOVA and Bonferroni post hoc tests to correct for multiple testing, as appropriate. Survival was plotted using the Kaplan-Meier method and survival between groups was compared with the log-rank test. Average fluid requirements over specific time periods were analyzed by linear regression analyses. A two-tailed P < .05 was considered significant. Data analyses were calculated with the GraphPad Prism program (GraphPad Software, San Diego, CA, USA). 
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